Evaluating AHSP as a biomarker for sickle cell disease
Official title: Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"
Run by Centre Hospitalier de Saint-Denis · NCT06735625 · Data updated 2026-11-12
This study is testing if the levels of a protein called AHSP in the blood can help doctors better understand and manage sickle cell disease in both adults and children.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 3 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Centre Hospitalier de Saint-Denis Academic / other |
| Locations | 1 site (Saint-Denis) |
| Status | Recruiting |
| Started | March 6, 2025 |
| Main results expected | March 20, 2026 |
| Study ends | January 20, 2027 |
| Registry record updated | April 2, 2025 |
| Trial ID | NCT06735625 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults and children aged 3 years and older with known SS or Sβ0 phenotypes.
✕Probably not a fit
Patients with hemoglobin disorders other than sickle cell disease will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the concentration of AHSP in blood samples from both adult and pediatric patients with sickle cell disease. It involves the collection of clinical data and blood samples, which are then analyzed for biochemical and hematological measurements. The study aims to correlate AHSP levels with various patient parameters to assess its potential as a biomarker for sickle cell disease. The research is conducted by a team of investigators at the Centre Hospitalier de Saint-Denis and involves collaboration with Inserm U955.
Why it matters
Potential benefit: If successful, this study could provide a new biomarker for better diagnosis and management of sickle cell disease.
How similar studies have gone: While the approach of using AHSP as a biomarker is novel, similar studies have shown promise in identifying biomarkers for sickle cell disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Inclusion Criteria for Sickle Cell Patients 1. Adults: \> 15 years and 6 months 2. Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 3. Known SS or Sβ0 phenotypes Inclusion Criteria for Control Patients. 1 -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration -Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder 4-Blood sample planned as part of medical care Exclusion Criteria: 1. Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients) 2. Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients) 3. Transfusion less than 3 months ago 4. Chronic active viral disease: hepatitis B, C, HIV 5. Current infections or known inflammatory pathologies 6. Known hyper or hypothyroidism or subject treated with levothyroxine 7. Active tumor pathology or remission for less than 5 years 8. Oral corticosteroid therapy in progress 9. Participation in interventional biomedical research 10. Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor. 11. Non-affiliation to a social security system
Where it's running
-
Centre Hospitalier de Saint-Denis
Saint-Denis, France Recruiting
Study contacts
- Study coordinator: Stéphanie NGO, Coordinating Investigator
- Email: stephanie.ngo@ch-stdenis.fr
- Phone: stephanie.ngo@ch-stdenis.fr
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Recognizing dapagliflozin overdose in ICU patients admitted for metformin poisoning.
This project will see if clinical signs and routine lab tests can help doctors tell whether adults in the ICU for metformin poisoning also took too much dapagliflozin.
-
Comparing how the uterus expands during hysterosonography in women monitored for fertility
This test sees if uterine volume changes measured during hysterosonography differ between women receiving IVF/ICSI care for infertility and women who are apparently fertile.
-
Single antibiotic versus two antibiotics for Pseudomonas bone infection
This study will test whether one antibiotic works as well as two for adults with bone infections caused by Pseudomonas aeruginosa.
-
Antibiotic approaches for Stenotrophomonas maltophilia pneumonia in ICU patients
This study tests whether using one antibiotic versus two, and whether treating for 7 days versus 14 days, helps adults on ventilators in the ICU with Stenotrophomonas maltophilia pneumonia survive and avoid recurrence.
-
Non-invasive blood pressure monitoring in ICU with the DARE device
This study tests whether the DARE non-invasive monitor can reliably measure blood pressure and other vital signs in adults in the ICU who have invasive arterial and urinary catheters.
-
Understanding how migrant patients with type 2 diabetes view food in their care
This study looks at how migrant patients with type 2 diabetes think about food and how it affects their diabetes care, to help create better support for them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.